1 long-form article and 1 pre-market mention covering $AZN from AskMelon Research.
AstraZeneca closed Q1 2026 with $15.29 billion in revenue, up 8% at constant currency and 13% as reported, with an oncology franchise that grew 16% to $6.8 billion and now supplies 44% of the top line…
Palantir's after-hours blowout — EPS $0.41 vs $0.35 est, revenue $1.94B (+93% YoY), full-year guide raised $500M to $8.15–8.16B — has NQ futures +0.60% and XLK pre-market +1.22%, but the real stakes a…